Lithium cation

Generic Name: Lithium cation

Drug Type: Small Molecule

Chemical Formula: Li

CAS Number: 7439-93-2

Unique Ingredient Identifier: 8H8Z5UER66

Background: Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.

Indication: Lithium, in its salt forms, is used as a mood stabilizer and for the treatment of depression and mania. It is most frequently prescribed in the treatment of bipolar disorder.

Associated Conditions: Bipolar Disorder (BD), Depression, Depression, Bipolar, Acute Manic episode

Clinical Trials

PRASED - Preventing Relapse After Successful Electroconvulsive Therapy for Depression

Not Applicable

Active, not recruiting

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Lithium

First Posted Date: 2024-12-30

Last Posted Date: 2024-12-30

Lead Sponsor: Universiteit Antwerpen

Target Recruit Count: 109

Registration Number: NCT06751875

Locations: 🇧🇪
Collaborative Antwerp Psychiatric Research Institute (CAPRI), Wilrijk, Antwerp, Belgium

A Study to Evaluate the Effects of Lithium and Valproic Acid on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium and Valproic Acid in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Xanomeline/Trospium Chloride
Drug: Lithium
Drug: Valproic Acid

First Posted Date: 2024-12-12

Last Posted Date: 2025-03-06

Lead Sponsor: Karuna Therapeutics

Target Recruit Count: 88

Registration Number: NCT06729970

Locations: 🇺🇸
CenExel Collaborative Neuroscience Research, LLC - Los Alamitos, Los Alamitos, California, United States

Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy

Phase 2

Recruiting

Conditions: Cognitive Decline
Radiotherapy Side Effect
Brain Tumor
Late Effect of Radiation
Cognitive Impairment
Radiotherapy; Complications
Memory Impairment

Interventions: Drug: Placebo
Drug: Lithium

First Posted Date: 2023-09-22

Last Posted Date: 2024-04-12

Lead Sponsor: Region Stockholm

Target Recruit Count: 84

Registration Number: NCT06051240

Locations: 🇸🇪
Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden
🇸🇪
HOPE, Stockholm, Sweden

Lithium Versus Anticonvulsants and the Risk of Physical Disorders

Completed

Conditions: Bipolar Disorder

First Posted Date: 2023-08-22

Last Posted Date: 2023-08-22

Lead Sponsor: Mental Health Services in the Capital Region, Denmark

Target Recruit Count: 169285

Registration Number: NCT06005155

Locations: 🇩🇰
Psychiatric Center Copenhagen, Copenhagen, Denmark

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Phase 3

Recruiting

Conditions: Bipolar Depression

Interventions: Drug: Escitalopram
Drug: Sertraline
Drug: Venlafaxine
Drug: Lithium
Drug: Valproate acid
Drug: Quetiapine
Drug: Bupropion

First Posted Date: 2023-08-03

Last Posted Date: 2025-05-16

Lead Sponsor: Dr. Inge Winter

Target Recruit Count: 418

Registration Number: NCT05973786

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
🇩🇪
Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz, Mainz, Germany

and more 10 locations